The epidemic of Wuhan pneumonia (novel coronavirus disease, COVID-19) is difficult to stop, two vaccines developed by Western pharmaceutical companies have been put into use, and China is also doing its best to develop a domestic vaccine, but the Chinese company “KeXing Biologicals” has recently repeatedly delayed the release of data from the phase III clinical trial in Brazil, so that Brazilian President Bossonaro could not help but publicly question, saying that “the effectiveness of the KeXing vaccine seems to be very low”.
Kexing Biologicals cooperated with Instituto Butantan, a Brazilian biological research center, to conduct the Phase III clinical trial of the martial lung vaccine “CoronaVac” in the state of São Paulo, Brazil, but the detailed trial data originally scheduled to be released in early December were repeatedly postponed, and on the 23rd, it was again announced that the release was delayed by The Institute announced on the 23rd that it would delay the release of the data for 15 days. The institute claimed that the efficacy of the vaccine reached more than 50% of the protection required by Brazil’s national health authorities, but it still had to analyze and integrate the results of other vaccine trials conducted in Indonesia and Turkey, and the delay had nothing to do with the vaccine’s effectiveness.
The Washington Times reported on the 24th that Brazilian President Jair Bolsonaro, who has repeatedly criticized the lack of openness and transparency in China’s vaccine research and development process, said in a live broadcast on a social media platform on the 24th that “the efficacy of the Kexing vaccine seems to be very low,” but did not elaborate further.
There are currently two vaccines in circulation around the world, including those from the American pharmaceutical company Pfizer and the German biotech company BioNTech, as well as those from the American pharmaceutical company Moderna, the former of which has been approved for emergency use by the United States, the United Kingdom, the European Union, Singapore and many other countries. Brazil has not yet signed a contract with these two U.S. pharmaceutical companies, but only plans to use the Kexin vaccine, and has also ordered 100 million doses of vaccine from the British pharmaceutical company AstraZeneca.
Recent Comments